Updated September 11, 2026. On September 8, Brazil’s health regulator Anvisa approved an expanded use of MenQuadfi, a conjugate meningococcal vaccine against serogroups A, C, W and Y, for pediatric use from 6 weeks of age. The change matters because it broadens the product’s authorized age range in Brazil, but it does not, by itself, mean that Brazil’s public health system (SUS) now provides MenQuadfi from 6 weeks or that the National Vaccination Schedule was automatically changed.
The key distinction is institutional: regulatory registration and indication, incorporation into SUS, and the public vaccination schedule are connected but separate steps. Keeping them distinct prevents a health-regulatory authorization from being read as if it were also a new vaccination policy.
What Anvisa authorized on September 8, 2026
According to Anvisa’s official announcement, MenQuadfi is now indicated for adult and pediatric use from 6 weeks of age. It is a conjugate meningococcal vaccine administered intramuscularly and intended to prevent invasive meningococcal disease caused by serogroups A, C, W and Y of Neisseria meningitidis.
The agency said its integrated safety assessment included data from 6,060 infants aged 6 weeks to under 12 months who received at least one MenQuadfi dose in one-, two- or three-dose primary schedules, as well as 5,373 children who received a booster dose from 12 months of age. According to Anvisa, the results showed a safety profile consistent with what is expected for conjugate meningococcal vaccines, with no new relevant safety concerns identified.
The immediate practical effect of the decision is regulatory: the approved age range for the product in Brazil is broader. That is different from saying that every child should receive the vaccine at 6 weeks or that the product automatically became part of the SUS routine at that age.
Why Anvisa’s authorization does not automatically change SUS
Conitec itself explains the difference between its role and Anvisa’s. Anvisa evaluates aspects such as efficacy and safety to authorize the marketing and use of a health technology in Brazil. For a technology to be incorporated into SUS, an additional assessment considers evidence of effectiveness, comparison with available alternatives, the magnitude of expected benefits and risks, economic evaluation, budget impact and logistical aspects.
In other words, health-regulatory authorization is a necessary condition for many technologies, but it is not the same as a decision to finance and provide them through SUS. A change in a vaccine’s regulatory label may allow use in a younger age group without deciding which vaccine the public program will purchase, at what ages, or under which schedule.
When an incorporation decision is made, the process still involves an official publication and implementation by the Ministry of Health. Conitec states that, after a decision to incorporate a technology, the technical areas have up to 180 days to make it available in SUS, because operational steps such as price negotiation, procurement, distribution and the preparation of protocols or use guidance may still be required.
What the National Vaccination Schedule shows now
In the Ministry of Health’s National Vaccination Schedule checked on September 11, 2026, the routine childhood schedule lists meningococcal C vaccine at 3 months and 5 months, and one meningococcal ACWY dose at 12 months. Therefore, MenQuadfi’s expanded indication from 6 weeks should not be read as proof that the public schedule has already moved MenACWY vaccination to that age.
| Layer | What is confirmed | What cannot be concluded automatically |
|---|---|---|
| Health regulation | MenQuadfi is indicated in Brazil from 6 weeks of age. | That every child should receive the vaccine exactly at 6 weeks. |
| SUS incorporation | Health technologies follow a separate assessment process within the Ministry of Health/Conitec. | That the new regulatory indication has already become routine SUS provision. |
| National schedule | As of September 11, 2026, the public schedule lists MenC at 3 and 5 months and MenACWY at 12 months. | That MenQuadfi automatically replaced the vaccine or schedule already used by the National Immunization Program. |
Three different questions that are often treated as one
1. Can the vaccine be used from 6 weeks?
Under Anvisa’s approved indication for MenQuadfi, yes: the authorized age range now begins at 6 weeks. This defines the approved regulatory age threshold in Brazil, within the conditions of the product label and the relevant professional assessment.
2. Does SUS already provide MenQuadfi from 6 weeks?
Anvisa’s authorization alone does not establish that. To answer a public-provision question, incorporation decisions and, above all, the current rules and schedule of the National Immunization Program need to be checked. At the time of this update, the public schedule reviewed does not show MenQuadfi starting at 6 weeks.
3. Has the childhood vaccination schedule changed?
Not automatically because of the regulatory decision. Changes to Brazil’s national schedule depend on separate decisions and acts by the Ministry of Health. That is why the safest source for what is routinely offered through SUS is the updated official schedule, not only a news item about a product registration.
What the change may mean outside the public routine
The broader authorized age range may affect the possibility of using the product in private services, provided it is commercially available and used in line with the approved label and the responsible professional’s assessment. Even so, “authorized from 6 weeks” does not mean “recommended for everyone at 6 weeks.”
Dose schedules, intervals, vaccination history, clinical conditions, product availability and applicable recommendations all need to be considered in care. This article does not replace individualized medical guidance and should not be used to start, bring forward, replace or complete a vaccination schedule without appropriate assessment.
Where to check each type of information
- Approved indication and regulatory change: check Anvisa and the current approved product information.
- SUS incorporation process: check Conitec, its assessments, public consultations and published decisions.
- Vaccines and ages routinely offered publicly: check the National Vaccination Schedule and the technical instructions of the National Immunization Program.
What to watch after Anvisa’s expansion
The relevant signals for a possible SUS change are different from the regulatory announcement. They include a request to assess incorporation or a change in use, Conitec documents, a formal Ministry of Health decision, and an update to the schedule or technical instructions of the National Immunization Program. If any of these steps occurs, the date and scope of the change should be checked in the corresponding official act.
Until then, the most precise reading is: MenQuadfi is authorized for use from 6 weeks of age in Brazil, but public vaccination policy does not automatically change with that decision. For families and caregivers, the current official schedule remains the reference for routine SUS vaccination; for individual situations, guidance should come from a qualified health service or professional.
